LONDON (Alliance News) - Akers Biosciences Inc said Wednesday that it had inked a sales and distribution agreement with Typenex Medical LLC for its PIFA Heparin/PF4 and PIFA PLUSS Platelet Factor 4 test kits.
Akers said that the agreement was part of its strategy to accelerate sales of the two tests to hospitals. The PIFA Heparin test is used for the diagnosis of Heparin-Induced Thrombocytopenia, an allergy to blood thinner Heparin. The PLUSS PF4 test is for thrombosis.
No financial details of the agreement were disclosed.
Shares in Akers Biosciences were trading down 3.7% at 260.00 pence Wednesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
